![]() Under the terms of the acquisition agreement, Clade has acquired all outstanding shares of Gadeta, making it a wholly owned subsidiary of Clade. The integration of Gadeta’s g/d TCR targeting technology is complementary to Clade’s cellular platform technology and will enhance the development of engineerable, off-the-shelf, scalable, and consistent stem-cell based medicines. The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies. These g/d TCRs recognize unique patterns or targets on the surface of cancer cells that signal that they are diseased, thereby specifically targeting cancer cells and sparing healthy cells. The company developed a proprietary platform to engineer novel g/d TCRs that possess broad tumor targeting capabilities. Gadeta is an international R&D company, focused on innovative immunotherapies for cancer. ![]() (“Gadeta”), a cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. 02, 2023 (GLOBE NEWSWIRE) - Clade Therapeutics (“Clade”), a biopharmaceutical company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, today announced that it has completed the acquisition of Gadeta B.V. g/d TCR candidate integrated into Clade’s solid tumor pipelineīOSTON, Oct. proprietary gamma/delta (g/d) TCR universal targeting platform technology, Clade Therapeutics Announces the Acquisition of Gadeta B.V.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |